Roche scores FDA priority review for risdiplam, threatening Biogen and Novartis SMA meds

25th November 2019 Uncategorised 0

Roche’s risdiplam, a potential 2020 entrant in spinal muscular atrophy, scored a FDA priority review on Monday. Analysts expect the med to bring in blockbuster sales at peak as it challenges Biogen’s Spinraza and Novartis’ gene therapy Zolgensma. The FDA set a May 24, 2020, decision deadline.

More: Roche scores FDA priority review for risdiplam, threatening Biogen and Novartis SMA meds
Source: fierce